Table 1.

Long-term Effects of Treatment

Measures	Baseline		End of Treatment		6 Month Follow-up		12 Month Follow-up
	M	SD	M	SD	M	SD	M	SD
Sleep Diaries
TST (min)	384.19	63.76	382.41	59.39	390.33	72.13	380.32	109.00
TWT (min)	100.21	60.84	42.56*	32.93	49.23*	34.64	47.65*	31.69
SOL (min)	33.15	23.69	15.58	10.13	20.37	15.03	20.16	19.56
WASO (min)	42.94	45.32	14.04	12.80	17.01	16.23	20.50	17.90
TWAK (min)	24.12	21.76	12.93	16.93	11.85	17.19	11.50	16.11
TIB (min)	483.41	78.14	424.97	53.03	439.36	75.81	422.76	116.86
SE (%)	79.97	10.17	89.93*	7.97	88.93*	7.95	89.91*	10.28
NWAK	2.37	1.82	1.28	1.33	0.87	0.62	1.40	1.31
Sleep Quality	5.85	1.09	6.49	1.13	6.79*	1.30	6.70	1.23
Daytime Sleepiness	4.18	1.84	3.97	2.04	3.54	1.88	3.53	1.89
Daytime Tiredness	4.21	1.63	4.23	1.75	3.49*	1.79	3.46	2.02
PSAS Total	32.90	8.04	25.14*	5.84	27.33*	8.06	27.57	6.55
Cognitive	19.86	5.65	14.76	5.20	16.05	5.81	16.24	4.41
Somatic	13.05	3.69	10.38	2.27	11.29	3.29	11.33	3.06
GSES	6.70	2.92	3.00*	2.17	3.05*	3.05	2.81*	3.14
ISI	14.65	4.18	8.29*	3.38	8.02*	4.40	7.10*	3.55
KIMS Total	132.48	11.79	135.52	15.80	136.24	13.84	136.95	14.85
Observe	34.33	5.78	36.52	7.30	36.43	5.91	39.76	7.15
Describe	29.10	5.71	29.81	6.51	29.38	5.97	29.43	6.19
Awareness	30.67	5.56	31.57	6.19	31.62	6.60	31.19	5.61
Accept	34.19	5.10	33.48	6.87	34.95	7.03	35.48	6.40
PANAS
Positive	33.71	6.01	34.95	6.08	32.57	6.45	34.33	6.61
Negative	17.14	4.97	15.52	4.07	16.05	4.19	15.52	4.07

Note. Analyses were conducted on selected variables of interest. Asterisk (*) indicates levels that were significantly different from baseline on post-hoc comparisons. Sleep quality ranges from 1 (very poor) to 10 (excellent). Daytime sleepiness and tiredness are rated from 1 to 10 with higher numbers reflecting higher levels of sleepiness / tiredness respectively. Baseline means and standard deviations for ISI and GSES are based on n = 20 due to incomplete data for one participant.